Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials-Reference-Cited by-同舟云学术

Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials

Published:2017-11-23 Issue:1 Volume:57 Page:135-140
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Jensen Maj-Britt¹,Nielsen Torsten O.²,Knoop Ann S.³,Laenkholm Anne-Vibeke⁴,Balslev Eva⁵,Ejlertsen Bent¹³

Affiliation:

1. Danish Breast Cancer Cooperative Group (DBCG), Secretariat and Statistical Office, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;

2. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada;

3. Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;

4. Department of Surgical Pathology, Zealand University Hospital, Slagelse, Denmark;

5. Department of Pathology, Herlev University Hospital, Herlev, Denmark

Publisher

Informa UK Limited

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2017.1400181

Reference31 articles.

1. Survival in Untreated and Treated Cancer

2. Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast Cancer

3. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy

4. Polychemotherapy for early breast cancer: an overview of the randomised trials

5. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dynamic ctDNA tracking stratifies individual relapse risk for early triple negative breast cancer patients receiving neoadjuvant chemotherapy;2024-07-10

2. A hierarchical approach to combine histological grade and immunohistochemical factors to identify high-risk luminal breast cancers;ecancermedicalscience;2022-05-04

3. The benefits of trastuzumab in the treatment of HER2+ breast cancer as a function of exposure time;ecancermedicalscience;2022-01-20

4. Analysis of the Mechanism of Breast Metastasis Based on Image Recognition and Ultrasound Diagnosis;Journal of Healthcare Engineering;2021-10-11

5. A validated algorithm for register-based identification of patients with recurrence of breast cancer—Based on Danish Breast Cancer Group (DBCG) data;Cancer Epidemiology;2019-04